BF-1

BF-1 is highly selective and potent 5-HT2B receptor which is being developed for the reduction of the frequency and intensity of migraine attacks. BF-1 intervenes at an early stage of the chemical cascade causing the migraine attacks. The compound prevents the release of second messengers, which initiate a self reinforcing inflammatory cascade ultimately perceived by the patient as migraine headache. Drugs available on the market for the prevention of migraine attacks generally cause severe side effects, causing most patients to discontinue the treatment before a positive therapeutic outcome is obtained. In contrast to the latter group of drugs, BF-1 exhibits a very high receptor selectivity, due to which, according to the scientists at Biofrontera, the risk of side effects can be considered very small.